Rich Pharmaceuticals' Study Drug RP-323 (TPA) Elevates White Blood Cells (WBCs) Which Play a Vital Role Fighting Infections, and in Immunotherapy

BEVERLY HILLS, CA, March 06, 2018 -- Rich Pharmaceuticals, Inc. (OTC: RCHA), is a Biopharmaceutical Company focused on developing and commercializing innovative therapies in oncology using its study drug RP-323 (TPA). Multiple clinical studies have shown a significant increase in WBCs in patients with solid tumors who suffered from low WBCs counts, and the studies show that RP-323 plays a major part in the developmental processes that are vital to many patients’ treatment and recovery.

"In one of the studies with 52 patients, all but one of the patients treated with an infusion of our drug TPA increased the number of WBCs, some significantly.  We know that WBCs are key to fighting disease and are vital to many patients' treatment and recovery," said Rich Pharmaceuticals CEO Ben Chang. 

“Physicians become concerned if the number of WBCs fall or rise out of the healthy range since they help fight infections by attacking bacteria, viruses, and germs.  Having a higher or lower number of WBCs may be an indication of an underlying condition,” explained Mr. Chang. “The ability to regulate WBC is a key element in immunotherapy.  Immunotherapy is the treatment that stimulates your body’s own immune system to help fight cancer.”

About Rich Pharmaceuticals:

Rich Pharmaceuticals, Inc. is a clinical-stage Biopharmaceutical Company focused on developing innovative therapies in oncology, with initial concentration in treating Acute Myelocytic Leukemia (AML), Hodgkin's Lymphoma (HL) and other blood related diseases. It is currently in Phase 1/2 clinical trials for the treatment of AML and HL. Rich Pharmaceuticals' goal is to extend refractory patients life expectancy and increase quality of life. Learn more at www.richpharmaceuticals.com.

Forward-Looking Statements:

This news release contains "forward-looking statements" as that term is defined in Section 27(a) of the Securities Act of 1933, as amended, and Section 21(e) of the Securities Exchange Act of 1934, as amended. Statements in this press release that are not purely historical are forward-looking statements and include any statements regarding beliefs, plans, expectations or intentions regarding the future. Such forward-looking statements include, among other things, references to novel technologies and methods, our business and product development plans, our financial projections or market information. Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, the inherent uncertainties associated with developing new products or technologies and operating as a development stage company, our ability to raise the additional funding we will need to commence clinical trials and to continue to pursue our business and product development plans, including the business and product development plans contained in this news release, our ability to develop and commercialize products based on our technology platform, competition in the industry in which we operate and market conditions. These forward-looking statements are made as of the date of this news release, and we assume no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements. Although we believe that any beliefs, plans, expectations and intentions contained in this press release are reasonable, there can be no assurance that any such beliefs, plans, expectations or intentions will prove to be accurate. Investors should consult all of the information set forth herein and should also refer to the risk factors disclosure outlined in the reports and other documents we file with the SEC, available at www.sec.gov.

Contact:

Paul Knopick

[email protected]

940.262.3584